Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-05-06

Clinical Trial Update: Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ceftobiprole for Staphylococcus aureus bacteremia has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ceftobiprole (ceftobiprole)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Staphylococcus Aureus Bacteremia | Phase 3 | Status: COMPLETED | Results posted: 2023-05-06